Bimagrumab: The Weight Loss Drug That Builds Muscle Instead of Losing It

The problem bimagrumab solves

Every GLP-1 drug shares one structural weakness: 25-40% of the weight lost is lean mass — muscle included. For general patients that's manageable; for older adults, athletes, and anyone planning long-term use, it's the single biggest downside of the drug class. Bimagrumab attacks it from a completely different direction: it blocks activin type II receptors (ActRII), the biological brake on muscle growth. Remove the brake and muscle grows even in a calorie deficit — while fat mass drops.

The data that made Eli Lilly buy it

• Fat loss: ~20% reduction in total body fat mass in the key Phase 2 trial (in type 2 diabetes patients).
• Muscle gain: ~3-4% lean mass increase during weight loss — unheard of with any appetite drug.
• Body recomposition: net effect is fat-dominant loss with muscle spared or added — the composition outcome every obesity drug wants.

Eli Lilly acquired the program and is running trials combining bimagrumab with incretin drugs — the logic being GLP-1 handles appetite/calories while bimagrumab handles composition. If it works, it effectively solves GLP-1 muscle loss at the pharmacological level.

What to do until then

The muscle-protection toolkit that exists today is behavioral, not pharmaceutical — and it works: ~1g protein per lb of goal weight, resistance training 3-4x per week, slower loss targets (under 1% body weight/week), and creatine. Patients who do all four keep the vast majority of their lean mass on GLP-1s. Athletes should see our athlete protocol; seniors have extra stakes — see GLP-1 for seniors.

Frequently asked questions

What is bimagrumab?

Bimagrumab is a monoclonal antibody that blocks activin type II receptors — the brake that limits muscle growth. Blocking it produces fat loss and muscle gain simultaneously: in a key trial, participants lost ~20% of body fat while gaining ~3-4% lean mass — body composition changes no GLP-1 achieves alone.

Does bimagrumab work with semaglutide?

That's the bet — trials are testing bimagrumab combined with semaglutide to see if it can fix GLP-1's main weakness: 25-40% of GLP-1 weight loss is lean mass. If adding bimagrumab converts that into fat-dominant loss with muscle preserved or gained, it would be the ideal combination.

Is bimagrumab available?

No — it's investigational, in clinical trials after Eli Lilly acquired the asset (originally Novartis/Versanis). It cannot be prescribed or bought. Gray-market 'bimagrumab' should be treated as counterfeit.

When will bimagrumab be approved?

Unknown — likely 2028+ if trials succeed. Eli Lilly is running combination studies with tirzepatide/semaglutide, which take years. It's one of the most-watched assets in the obesity pipeline precisely because it solves the muscle-loss problem.

How do I protect muscle on GLP-1s today?

Without bimagrumab: protein at ~1g per lb of goal weight, resistance training 3-4x weekly, slower weight loss targets, and creatine. Our GLP-1 muscle loss guide has the full protocol.

Bottom line

Bimagrumab is the most interesting muscle-preservation play in the obesity pipeline — but it's a trial drug. Today, protein + lifting does the same job free: protect your lean mass on a $119/month program now, and let bimagrumab be a 2028 upgrade if it lands.